A 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's Disease
Aim: To investigate whether 1-step titration of the rivastigmine patch (initiated at 5 cm2 and titrated to 10 cm2 after 4 weeks) is well tolerated in Japanese patients with Alzheimer's disease (AD) as compared to 3-step titration (initiated at 2.5 cm2 and titrated by 2.5 cm2 every 4 weeks to 10...
Main Authors: | Yu Nakamura, Christine Strohmaier, Kaoru Tamura, Naoko Kataoka, Masayuki Nakano, Shoichiro Oda, Kazuma Nishimura, Akira Homma |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2015-09-01
|
Series: | Dementia and Geriatric Cognitive Disorders Extra |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/439269 |
Similar Items
-
Efficacy, Safety, and Tolerability of Switching from Oral Cholinesterase Inhibitors to Rivastigmine Transdermal Patch with 1-Step Titration in Patients with Mild to Moderate Alzheimer’s Disease: A 24-Week, Open-Label, Multicenter Study in Japan
by: Kengo Ueda, et al.
Published: (2019-08-01) -
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer’s Disease
by: Yu Nakamura, et al.
Published: (2011-06-01) -
The Effect of Vascular Risk Factors on the Efficacy of Rivastigmine Patch and Capsule Treatment in Alzheimer’s Disease
by: M.R. Farlow, et al.
Published: (2011-06-01) -
Rivastigmine patch (Exelon patch) compared to melatonin patch in prevention of postoperative delirium in the elderly
by: Rania Maher Hussien, et al.
Published: (2020-08-01) -
The specific features of using a rivastigmine transdermal formulation in Alzheimer’s disease
by: Elena Evgenyevna Vasenina, et al.
Published: (2012-09-01)